Brought to you by

Events

Advancing mHealth: Can the smartphone pioneer a new self-care agenda?

Wednesday 3rd February 2016
The Hospital Club, Covent Garden, London

Download the Event Summary now

Publication

New data, new methods, new insights

Discover the event summary for the Real-World Evidence Symposium 2016 which drew thought leaders from diverse fields to shape the exciting possibilities for patient/citizen-generated data.

Whitepaper

Hepatitis C: Inequalities in Access to Medicines

Based on a unique view of the Hepatitis C patient treatment journey, this White Paper quantifies the current state of real-world practice and the scale of inequalities to access. At a time of major NHS reform and restructuring, its findings underscore the imperative for action to redress the balance and realise the benefits of new generation treatments.

Publication

Driving Equity in Health: Evolving the Healthcare System to Ensure Equitable Access for All: Critical Review

How can the healthcare system evolve to ensure that all patients have access to the same levels of treatment, regardless of their background or current social situation?

Events

Driving Equity in Health: How Social Determinants Impact Innovation

Thursday 8th October 2015
The King’s Fund, London

Video

Prescribing the best apps

This short animation available via our YouTube channel provides an insight into the growing world of health apps.

Whitepaper

Impact of cost-per-QALY reimbursement criteria on access to cancer drugs

“Impact of cost-per-QALY reimbursement criteria on access to cancer drugs” from IMS Institute for Healthcare Informatics looks into the analysis undertaken by the IMS Consulting Group , aimed at developing an understanding of the impacts that alternative approaches to reimbursement decisions have on patient care.

Webinar

Market Developments in Diabetes- current and future treatment trends in major pharmerging markets

This webinar from IMS looks at the dynamics of the global diabetes market.

Whitepaper

Patient Apps for Improved Healthcare: From Novelty to Mainstream

In this White Paper from the IMS Institute for Healthcare Informatics, experts look into the ever-growing popularity of patient apps – whether they do improve health and their move from novelty into mainstream.

Webinar

The Price is Right? Delivering UK Access for Niche Patient Populations

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the ramifications for high priced/innovative treatments delivering beneficial outcomes to defined patient populations in the UK? How can pharma navigate these seemingly choppy waters of access for rare disease treatments and orphan drugs?

Whitepaper

The Third Sector - A growing opportunity in the pharmaceutical market?

In this White Paper from IMS Health Intelligence Applied, experts explore the opportunity in the space in-between innovative and generic products including the route of administration, product combinations, dosage form and strength and value for patients and payers.

Whitepaper

Improving the management of chronic conditions through medicines optimisation

This White Paper from IMS Health looks at the treatment of rheumatoid arthritis in England.

Web-page Article

Six potential high-impact outcomes of NHS devolution for industry

In this article from PharmaPhorum, IMS Health’s Lead Senior Principal from Market Access, Angela McFarlane, looks at the significance of the recent Greater Manchester region reform and suggests six potential high impact outcomes for the pharmaceutical industry.

Webinar

Deals of 2013 – Big Pharma Opts for Alliances over Mergers & Acquisitions as Targeted Partnering Strategies Prevail

IMS Health’s John Bird, lead analyst of company intelligence, and IMS PharmaDeals’ Taskin Ahmed discuss recent trends in M&A and licensing deals

Whitepaper

Global Outlook for Medicines Through 2018

Global spending on medicines is forecast to reach nearly $1.3 trillion by 2018, an increase of around 30% from 2013.

Whitepaper

The new science of personalized medicine: Translating the promise into practice

Personalised medicine is presenting new challenges and opportunities for players within and beyond the health industry, redefining the health industry and disrupting existing business models. To compete in this market, organisations will need new approaches, new relationships, and new ways of thinking.

Whitepaper

Cell & Gene Therapies: Innovation to commercialisation

As part of the IMS Health Thought Leadership programme we are pleased to present this report: “Cell & Gene Therapies: Innovation to commercialisation” which asks how industry can bridge the gap between exceptional trial results and success in the market. 

Webinar

Can an early stage pipeline offset the loss of exclusivity for key ulcerative colitis and Crohn’s disease brands in the IBD market?

In this webinar, IMS Health’s Pam Narang, PhD., Autoimmune Analyst at Disease Insights, shares information about the inflammatory bowel disease (IBD) market focusing on current clinical and commercial market dynamics and opportunities.

Video

Transforming Mobile Health

In this video report available via our YouTube channel, Executive Director of IMS Institute for Health Informatics, Murray Aitken, gives an overview of our report: “Patient Apps for Improved Healthcare” and whether apps really can improve health outcomes and help save costs. 

Whitepaper

Developments in Cancer Treatments, Market Dynamics, Patient Access and Value: Global Oncology Trend Report 2015

This Global Oncology Trend Report from IMS Institute for Healthcare Informatics looks at the heightened excitement around prospects for major advances in cancer treatment.

Whitepaper

Understanding the Role and Use of Essential Medicines Lists

In this IMS Institute for Healthcare Informatics report, we look at the establishment of the concept of “essential medicines” and how it has become a critically important element of national health system, policies and practices. 

Whitepaper

Using big data to identify opportunity and drive informed change in secondary care

This report aims to explore the changing patterns of Non-Steroidal Anti-Inflammatory Drug (NSAID) dispensing in UK hospitals.